ConductScience.org, home

Comparison · NCT01523002-deaths

Arm A: Metoprolol DDI and Pyronaridine-artesunate 90-day Redosing vs Arm B: Pyronaridine-artesunate 60-day Redosing: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Arm A: Metoprolol DDI and Pyronaridine-artesunate 90-day Redosing vs Arm B: Pyronaridine-artesunate 60-day Redosing: deaths from any cause. Trial comparisons, record NCT01523002-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01523002-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.129wilson
Risk in group 2000.114wilson
Risk difference, group 1 minus group 20-0.1140.129newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Arm A: Metoprolol DDI and Pyronaridine-artesunate 90-day Redosing
Subjects will take 1 day of metoprolol followed by a 7 day wash out period; then 2 days of pyronaridine-artesunate followed by 1 day of pyronaridine-artesunate + metoprolol and then a 87 day follow-up period. Subjects will then receive pyronaridine-artesunate once daily for three days followed by a 40 day follow-up period and a study completion evaluation.
026EG000
Group 2Arm B: Pyronaridine-artesunate 60-day Redosing
Subjects will take pyronaridine-artesunate once daily for 3 days, followed by a 57 day follow-up period. Subjects will then take pyronaridine-artesunate once daily for 3 days followed by a 40 day follow-up period.
030EG001

Harm

What it counts
Total, all-cause mortality
Time frame
Arm A: 140 days + follow up if necessary Arm B: 103 days + follow up if necessary

Source ClinicalTrials.gov

Trial

Title
Drug Interaction Study of Pyronaridine-artesunate & Metoprolol, & Redosing Study of Pyronaridine-artesunate
NCT number
NCT01523002
Phases
PHASE1
Conditions
Malaria
Interventions
Metoprolol and pyronaridine-artesunate, pyronaridine-artesunate
Lead sponsor
Medicines for Malaria Venture
Results first posted
2023-12-14

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01523002-deaths